BR9714145A - Composto ou seu sal farmaceuticamente aceitável, composição farmacêutica, e, processos para tratar ou prevenir doenças relacionadas com a progesterona, câncer de mama, câncer do ovário, histeromioma, endometriose, meningioma, mieloma, osteoporose, ou distúrbios climatéricos, para provocar um aborto, ou para prevenir oralmente a concepção - Google Patents

Composto ou seu sal farmaceuticamente aceitável, composição farmacêutica, e, processos para tratar ou prevenir doenças relacionadas com a progesterona, câncer de mama, câncer do ovário, histeromioma, endometriose, meningioma, mieloma, osteoporose, ou distúrbios climatéricos, para provocar um aborto, ou para prevenir oralmente a concepção

Info

Publication number
BR9714145A
BR9714145A BR9714145-3A BR9714145A BR9714145A BR 9714145 A BR9714145 A BR 9714145A BR 9714145 A BR9714145 A BR 9714145A BR 9714145 A BR9714145 A BR 9714145A
Authority
BR
Brazil
Prior art keywords
progesterone
pharmaceutically acceptable
prevent
breast cancer
hysteromyoma
Prior art date
Application number
BR9714145-3A
Other languages
English (en)
Other versions
BR9714145B1 (pt
Inventor
Kenichi Kirihara
Rie Shinei
Yasushi Kurata
Yuji Tabata
Kiyoshi Tanabe
Tseuneo Okonogi
Original Assignee
Meiji Seika Kaisha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Seika Kaisha filed Critical Meiji Seika Kaisha
Publication of BR9714145A publication Critical patent/BR9714145A/pt
Publication of BR9714145B1 publication Critical patent/BR9714145B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"COMPOSTO OU SEU SAL FARMACEUTICAMENTE ACEITáVEL COMPOSIçãO FARMACêUTICA, E, PROCESSOS PARA TRATAR OU PREVENIR DOENçAS RELACIONADAS COM A PROGESTERONA, CâNCER DE MAMA, CâNCER DO OVáRIO, HISTEROMIOMA, ENDOMETRIOSE, MENINGIOMA, MIELOMA, OSTEOPOROSE, OU DISTúRBIOS CLIMATéRICOS, PARA PROVOCAR UM ABORTO, OU PARA PREVENIR ORALMENTE A CONCEPçãO". Descreve-se compostos representador pela fórmula (I) a seguir ou seus sais farmaceuticamente aceitáveis e um processo para produzir os mesmos. Os compostos apresentam atividade inibidora de ligação de receptor de progesterona e, portanto, podem ser usados como agentes terapêuticos e profiláticos para doenças relacionadas com a progesterona. Especificamente, eles são úteis como agentes carcinostáticos para o câncer de mama e câncer de ovário, como agentes terapêuticos para o histeromioma, a endometriose, o meningioma, e o mieloma, abortivos, pílulas orais contraceptivas, e como agentes terapêuticos e profiláticos para a osteoporose e distúrbios climatéricos em que R^ 1^representa alquil ou aralquil,; R^ 2^representa um átomo de hidrogênio, alquilcarbonil, cicloalquilcarbonil, acil aromático, acil heteroaromático, acil heterocíclico saturado, alquil, alquenil, aralquil, carbamoil, alquilcarbamoil, carbamoil aromático, aralquilcarbamoil, alquilaminanocarbonil, cicloalquicarbamoil, alcoxicarbonil, ariloxicarbonil, tiocarbonil heteroaromático, tiocarbonil heterocíclico saturado, ou alquiltiocarbamoil: e R^3^representa um átomo de hidrogênio,um grupo hidroxil, alquilóxi, alquilcarbonilóxi, alquiltio, ou ariltio.
BRPI9714145-3A 1996-12-18 1997-12-18 composto ou seu sal farmaceuticamente aceitável e composição farmacêutica compreendendo o mencionado composto. BR9714145B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP33828096 1996-12-18
JP30889197 1997-11-11
PCT/JP1997/004683 WO1998027059A1 (fr) 1996-12-18 1997-12-18 Nouveaux derives de la tetrahydrobenzindolone

Publications (2)

Publication Number Publication Date
BR9714145A true BR9714145A (pt) 2000-02-29
BR9714145B1 BR9714145B1 (pt) 2009-05-05

Family

ID=26565726

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9714145-3A BR9714145B1 (pt) 1996-12-18 1997-12-18 composto ou seu sal farmaceuticamente aceitável e composição farmacêutica compreendendo o mencionado composto.

Country Status (10)

Country Link
US (1) US6077840A (pt)
EP (1) EP0947507B1 (pt)
JP (1) JP4201840B2 (pt)
KR (1) KR20000069498A (pt)
AU (1) AU727981B2 (pt)
BR (1) BR9714145B1 (pt)
CA (1) CA2275306C (pt)
DE (1) DE69732576T2 (pt)
ES (1) ES2236835T3 (pt)
WO (1) WO1998027059A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329416B1 (en) 1999-05-04 2001-12-11 American Home Products Corporation Combination regimens using 3,3-substituted indoline derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6380178B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Cyclic regimens using cyclocarbamate and cyclic amide derivatives
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6423699B1 (en) 1999-05-04 2002-07-23 American Home Products Corporation Combination therapies using benzimidazolones
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6355648B1 (en) 1999-05-04 2002-03-12 American Home Products Corporation Thio-oxindole derivatives
US6358947B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Tetracyclic progesterone receptor modulator compounds and methods
US6399593B1 (en) 1999-05-04 2002-06-04 Wyeth Cyclic regimens using cyclic urea and cyclic amide derivatives
US6444668B1 (en) 1999-05-04 2002-09-03 Wyeth Combination regimens using progesterone receptor modulators
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6319912B1 (en) 1999-05-04 2001-11-20 American Home Products Corporation Cyclic regimens using 2,1-benzisothiazoline 2,2-dioxides
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6498154B1 (en) 1999-05-04 2002-12-24 Wyeth Cyclic regimens using quinazolinone and benzoxazine derivatives
US6407101B1 (en) 1999-05-04 2002-06-18 American Home Products Corporation Cyanopyrroles
UA73119C2 (en) * 2000-04-19 2005-06-15 American Home Products Corpoir Derivatives of cyclic thiocarbamates, pharmaceutical composition including noted derivatives of cyclic thiocarbamates and active ingredients of medicines as modulators of progesterone receptors
JP2001316363A (ja) * 2000-04-28 2001-11-13 Meiji Seika Kaisha Ltd 安定な新規テトラヒドロベンズインドロン誘導体及びそれらの製造法
JP2001316364A (ja) * 2000-04-28 2001-11-13 Meiji Seika Kaisha Ltd 新規テトラヒドロベンズインドロン誘導体及びそれらの製造法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4014899A (en) * 1973-10-29 1977-03-29 Ciba-Geigy Corporation 5,6-Benzoisoindolines
US4952703A (en) * 1989-05-25 1990-08-28 Pfizer Inc. Intermediates for making 2-oxindole-1-carboxamides
IL101074A (en) * 1991-03-14 1997-09-30 Salk Inst For Biological Studi GnRH ANALOGS AND THEIR PREPARATION
US5712306A (en) * 1995-01-17 1998-01-27 Meiji Seika Kaisha, Ltd. Physiologically active substances PF1092A, PF1092B and PF1092C, and contraceptives and anticancer drugs containing the same as active ingredients
AU1733297A (en) * 1996-02-19 1997-09-02 Meiji Seika Kabushiki Kaisha Novel tetrahydronaphthofuranone derivatives and process for producing the same

Also Published As

Publication number Publication date
AU727981B2 (en) 2001-01-04
CA2275306A1 (en) 1998-06-25
DE69732576T2 (de) 2005-07-28
BR9714145B1 (pt) 2009-05-05
EP0947507B1 (en) 2005-02-23
ES2236835T3 (es) 2005-07-16
EP0947507A4 (en) 2002-05-02
AU7738098A (en) 1998-07-15
KR20000069498A (ko) 2000-11-25
WO1998027059A1 (fr) 1998-06-25
DE69732576D1 (de) 2005-03-31
JP4201840B2 (ja) 2008-12-24
EP0947507A1 (en) 1999-10-06
CA2275306C (en) 2007-07-31
US6077840A (en) 2000-06-20

Similar Documents

Publication Publication Date Title
BR9714145A (pt) Composto ou seu sal farmaceuticamente aceitável, composição farmacêutica, e, processos para tratar ou prevenir doenças relacionadas com a progesterona, câncer de mama, câncer do ovário, histeromioma, endometriose, meningioma, mieloma, osteoporose, ou distúrbios climatéricos, para provocar um aborto, ou para prevenir oralmente a concepção
CA2280905A1 (en) Highly lipophilic camptothecin derivatives
PT97689A (pt) Processo para a preparacao de composicoes farmaceuticas incorporando como ingrediente activo isoxazol-4-carboxilamida e hidroxialquilideno-cianoacetamida
BR9709959A (pt) Derivados tricìclicos de fenilamino substituìdo para o tratamento de doenças hiperproliferativas
BR0015911A (pt) Derivados de benzoimidazole úteis como agentes antiproliferativos
BR9709501A (pt) Composto, composição farmacêutica , e, processos para tratar ou prevenir a esquizofrrenia e para sintetizar um composto
MX9504630A (es) Nuevos derivados de la oxazolidinona, antagonista del receptor de adhesion, procedimiento para su preparacion y composiciones farmaceuticas que los contienen.
BR0010746A (pt) Derivados heterocìclicos úteis com agentes anticâncer
AR032438A1 (es) Compuesto derivado de indazol, composicion farmaceutica que lo comprende y su uso en la fabricacion de un medicamento para tratar enfermedades proteinquinasa dependientes
HN1998000074A (es) Derivados de macrolidos c-4 sustituidos
BR0010938A (pt) Derivados da 13-metil eritromicina
BR0312280A (pt) Composto ou um sal, solvato, solvato de tal sal ou uma prodroga do mesmo faarmaceuticamente aceitável, processo para prepará-lo, composição farmacêutica, uso do composto, métodos para produzir um efeito inibidor da absorção de colesterol, e para tratar condições hiperlipidêmicas em um animal de sangue quente, tal como o homem, que necessita de tal tratamento, combinação, e, uso desta
RU94036772A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования эндометриоза
BR0311806A (pt) Derivados heteroaril benzocondensado-amida de tienopiridinas úteis como agentes terapêuticos, composições farmacêuticas que os incluem e métodos para o seu uso
KR910004651A (ko) 5α-환원효소 억제제로서의 17β-아실-4-아자-5α-안드로스트-1-엔-3-온
BRPI9913138B8 (pt) derivado de quinolin-2-ona substituído com alquinila e composição farmacêutica contendo o mesmo
BRPI0411508A (pt) composto, formulação farmacêutica, uso de um composto, método para tratar doenças, e, processo para preparar um composto
BR0111377A (pt) Derivados de tiofeno úteis como agentes anticancerìgenos
BR9912240A (pt) Benzocicloheptenos, processo para a sua preparação, preparados farmacêuticos, que contêm os mesmos bem como seu emprego para a preparação de medicamentos
BR0109109A (pt) Composto, uso do mesmo, processo para prepará-lo, composição farmacêutica, e, método de tratar um estado doentio mediado por ccr5 em mamìferos
BR0111061A (pt) 1-aminoalquil-lactamas substituìdas e seu uso como antagonistas de receptor muscarìnico a61p 21/02
BR0012610A (pt) Novo derivado de difenilpiperidina
CA2270955A1 (en) Pharmaceutical composition containing morphinan derivative for treating drug dependence
AR001790A1 (es) Formulaciones para parches transdermicos que sirven para el tratamiento de condiciones modeladas de receptores muscarinicos
MX9606493A (es) Derivado de triterpeno y composicion medicinal.

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 28/07/2009, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2342 DE 24-11-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.